Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of weekly TransCon hGH versus daily Genotropin in prepubertal children with growth hormone deficiency
2016-001145-11Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in growth hormone deficiency (GHD) comparing Weekly TransCon hGH with Daily Genotropin (2 arms). Primary endpoint: Annualized height velocity at 52 weeks. Started Dec 2016; status: completed.
02
Drugs
lonapegsomatropinsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2016-001145-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001145-11.